Retraction Note: Interleukin 17 acts in synergy with B cell–activating factor to influence B cell biology and the pathophysiology of systemic lupus erythematosus

Doreau, Agnès; Belot, Alexandre; Bastid, Jérémy; Riche, Benjamin; Trescol-Biémont, Marie-Claude; Ranchin, Bruno; Fabien, Nicole; Cochat, Pierre; Pouteil‐Noble, Claire; Trolliet, Pierre; Durieu, I.; Tébib, Jacques; Kassai, Behrouz; Ansieau, Stéphane; Puisieux, Alain; Eliaou, Jean‐François; Bonnefoy, Nathalie

doi:10.1038/ni0914-894a

Cited by 4 publications

(2 citation statements)

References 1 publication

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A number of studies, mainly from Asian cohorts, showed a correlation of IL-17A levels or the number of Th17 cells with disease activity or organ damage (26)(27)(28)(29). However, one of the seminal studies has since been retracted (30). Our results, which include a PCA, indicate that IL-17A does not exhibit discernibly different characteristics across disease activity and organ damage states, which was a similar finding to that of Zhao et al (31), Cheng et al (32), and more recently, Vincent et al (33).…”

Section: Discussionmentioning

confidence: 99%

IL-17A levels in systemic lupus erythematosus associated with inflammatory markers and lower rates of malignancy and heart damage: Evidence for a dual role

Raymond¹,

Ostli-Eilertsen²,

Griffiths³

et al. 2017

Eur J Rheumatol

View full text Add to dashboard Cite

Objective: The interleukin 17 (IL-17) cytokine family is involved in a number of chronic inflammatory diseases. In spite of contradictory findings and a lack of causality in clinical studies, IL-17 inhibition for systemic lupus erythematosus (SLE) has regained attention as a potential therapeutic pathway, after demonstrating disease-modifying capabilities in ankylosing spondylitis. We investigated the clinical associations of interleukin 17 A (IL-17A) in patients with SLE.Material and Methods: A cross-sectional study was performed involving SLE patients (n=102; age: 49 years; 86% female) recruited from a regional registry. IL-17A levels were determined by immunoassay, disease activity by Systemic Lupus Erythematosus Disease Activity Index-2K (SLEDAI-2K), and cumulative damage by Systemic Lupus International Collaborative Clinics Damage Index (SDI) scores. Non-parametric techniques were used to examine the association between IL-17A and disease activity and autoantibody profiles were compared with healthy controls (n=31): principal component analysis (PCA) was used to determine the interplay of immune cells across disease states and damage development in SLE patients.Results: SLE patients had higher IgG levels, lower T-cell and B-cell counts, but median IL-17A levels did not differ from the controls (28.4 vs. 28.4 pg/mL, p=0.9). In SLE patients, IL-17A did not correlate with SLEDAI-2K or SDI, but was inversely related with age (correlation coefficients, Rs.=-0.29, p<0.05), systolic blood pressure (Rs.=-0.31, p<0.05), years of smoking (Rs.=-0.43, p<0.05), cumulative heart (Rs.=-0.22, p<0.05), and malignancy damage (Rs.=-0.18, p<0.05). Serological correlations for IL-17A existed with immunoglobulin G (IgG) levels (Rs.=0.21, p<0.05), high sensitivity C-reactive protein (hs-CRP) levels (Rs.=0.28, p<0.05), proteinuria (Rs.=0.64, p<0.05), and pre-albumin (Rs.=-0.22, p<0.05). Longitudinal data showed only modest fluctuation in IL-17A levels, independent of SLEDAI-2K. Conclusion:These results suggest that IL-17A, while participating in inflammation, may also serve a protective purpose in SLE patients.

show abstract

Section: Discussionmentioning

confidence: 99%

IL-17A levels in systemic lupus erythematosus associated with inflammatory markers and lower rates of malignancy and heart damage: Evidence for a dual role

Raymond¹,

Ostli-Eilertsen²,

Griffiths³

et al. 2017

Eur J Rheumatol

View full text Add to dashboard Cite

show abstract

“…Network analysis is an increasingly prevalent tool for representing the complexity of biological processes and how they relate to each other 2 3 4 5 . Identification of active sub-networks (modules) based on omics data sets can assist in explaining properties of the underlying biological system 6 . Networks are also used to integrate multi-source and multi-level data sets to improve the quality of the biological interpretations 7 .…”

mentioning

confidence: 99%

Systems view of adipogenesis via novel omics-driven and tissue-specific activity scoring of network functional modules

Nassiri

Lombardo

Lauria

et al. 2016

Sci Rep

View full text Add to dashboard Cite

The investigation of the complex processes involved in cellular differentiation must be based on unbiased, high throughput data processing methods to identify relevant biological pathways. A number of bioinformatics tools are available that can generate lists of pathways ranked by statistical significance (i.e. by p-value), while ideally it would be desirable to functionally score the pathways relative to each other or to other interacting parts of the system or process. We describe a new computational method (Network Activity Score Finder - NASFinder) to identify tissue-specific, omics-determined sub-networks and the connections with their upstream regulator receptors to obtain a systems view of the differentiation of human adipocytes. Adipogenesis of human SBGS pre-adipocyte cells in vitro was monitored with a transcriptomic data set comprising six time points (0, 6, 48, 96, 192, 384 hours). To elucidate the mechanisms of adipogenesis, NASFinder was used to perform time-point analysis by comparing each time point against the control (0 h) and time-lapse analysis by comparing each time point with the previous one. NASFinder identified the coordinated activity of seemingly unrelated processes between each comparison, providing the first systems view of adipogenesis in culture. NASFinder has been implemented into a web-based, freely available resource associated with novel, easy to read visualization of omics data sets and network modules.

show abstract

Knockdown of RSAD2 attenuates B cell hyperactivity in patients with primary Sjögren’s syndrome (pSS) via suppressing NF-κb signaling pathway

et al. 2021

View full text Add to dashboard Cite

Retraction Note: Interleukin 17 acts in synergy with B cell–activating factor to influence B cell biology and the pathophysiology of systemic lupus erythematosus

Abstract: Despite many attempts to replicate these results, the authors have been unable to confirm the original data showing that IL-17 alone or in combination with B cell-activating factor controls the survival of human B cells (Fig. 1a,b).

Cited by 4 publications

References 1 publication

IL-17A levels in systemic lupus erythematosus associated with inflammatory markers and lower rates of malignancy and heart damage: Evidence for a dual role

IL-17A levels in systemic lupus erythematosus associated with inflammatory markers and lower rates of malignancy and heart damage: Evidence for a dual role

Systems view of adipogenesis via novel omics-driven and tissue-specific activity scoring of network functional modules

Knockdown of RSAD2 attenuates B cell hyperactivity in patients with primary Sjögren’s syndrome (pSS) via suppressing NF-κb signaling pathway

Contact Info

Product

Resources

About